AGM Presentation
Read More
AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development
Read More
Commercialisation Agreement with Crossbeta Biosciences
Read More
AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation Technology
Read More
Collaboration Agreement with XL-Protein
Read More
Quarterly Review and Appendix 4C
Read More
Change of Director’s Interest Notice
Read More
Appendix 3B
Read More
AdAlta to present at forthcoming industry conferences
Read More
Update on Orphan Drug Designation
Read More